Pfizer demonstrated strong financial performance and strategic progress in 2024, with significant achievements in market leadership and pipeline advancements. While there are challenges with specific products and external factors such as the IRA, the overall sentiment is positive due to the robust execution and strategic positioning for future growth.

Company Guidance

In the fourth quarter of 2024 earnings call, Pfizer reported strong financial performance, meeting or exceeding strategic goals across various metrics. The company successfully integrated the Seagen business, enhancing its oncology capabilities, and reorganized its commercial operations into two divisions, U.S. and international, which improved its market presence. Pfizer achieved the top position in the 2024 IQVIA U.S. Field Force Ranking report and secured #1 or #2 spots in 70% of its targeted specialties. The company reported over a dozen approvals, seven pivotal study starts, and eight key Phase 3 readouts, reflecting robust pipeline progress. Financially, Pfizer ended 2024 with expanded margins, $11 billion invested in internal R&D, $7.8 billion in deleveraging, and $9.5 billion returned to shareholders through dividends. Looking ahead, Pfizer's 2025 priorities include enhancing R&D productivity, margin expansion, and continued focus on commercial excellence, with expectations for multiple key milestones in its R&D pipeline.

Strong Financial Performance in 2024

Pfizer reported revenues of $63.6 billion for 2024, with operational revenue growth excluding COVID products at 12%, exceeding expectations of 9% to 11%.

Successful Integration of Seagen Business

Pfizer successfully integrated Seagen, creating a strong oncology segment, which is expected to enhance Pfizer's position in the industry.

Commercial Excellence and Market Leadership

Pfizer achieved the top position in the 2024 IQVIA U.S. Field Force Ranking report, claiming the #1 or #2 spot in 70% of the specialties it focuses on.

Pipeline Progress and Approvals

Pfizer reported more than a dozen approvals in 2024, with seven pivotal study starts and eight key Phase 3 readouts, indicating a robust pipeline.

Strong Performance of Key Products

Key products such as Padcev, Eliquis, and Nurtec showed significant growth, with Padcev becoming the #1 prescribed first-line treatment for metastatic urothelial cancer in the U.S.

Financial Discipline and Shareholder Returns

Pfizer expanded margins and returned $9.5 billion directly to shareholders through dividends, while deleveraging by $7.8 billion.

---

Pfizer (DE:PFE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DE:PFE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 06, 2025	2025 (Q1)	0.68 / -	0.782	―	―	―
Feb 04, 2025	2024 (Q4)	0.45 / 0.60	0.095	530.00% (+0.51)
Oct 29, 2024	2024 (Q3)	0.59 / 1.01	-0.162	723.53% (+1.17)
Jul 30, 2024	2024 (Q2)	0.44 / 0.57	0.639	-10.45% (-0.07)
May 01, 2024	2024 (Q1)	0.49 / 0.78	1.173	-33.33% (-0.39)
Jan 30, 2024	2023 (Q4)	-0.15 / 0.10	1.087	-91.23% (-0.99)
Oct 31, 2023	2023 (Q3)	-0.08 / -0.16	1.697	-109.55% (-1.86)
Aug 01, 2023	2023 (Q2)	0.54 / 0.64	1.945	-67.16% (-1.31)
May 02, 2023	2023 (Q1)	0.94 / 1.17	1.545	-24.07% (-0.37)
Jan 31, 2023	2022 (Q4)	1.00 / 1.09	1.03	5.56% (+0.06)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

DE:PFE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 04, 2025	€25.59	€24.86	-2.89%
Oct 29, 2024	€25.86	€25.48	-1.46%
Jul 30, 2024	€27.49	€27.38	-0.40%
Jan 30, 2024	€23.90	€23.67	-0.98%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---